Simplifying Global Compliance
FDAnews Drug Daily Bulletin
U.S. Fabry Patients Petition for Same Fabrazyme Preference as EU
June 28, 2011
A group of U.S. patients with Fabry disease intensified their campaign to get an open license for Genzyme’s Fabrazyme during an ongoing shortage, citing preferential treatment of Fabry patients in Europe.
International Pharmaceutical Regulatory Monitor
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing